Reply to “Comment on ‘Pneumocystis jirovecii Pneumonia in Patients Treated for Solid Organ Malignancy’ ”
Ian Jackson, Raul Isern, Stephanie Jesina, Manasa Velagapudi, William Pruett
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPneumocystis jirovecii pneumonia detection and treatment · Tuberculosis Research and Epidemiology · HIV/AIDS drug development and treatment
TO THE EDITOR
We thank Khan and Ahmad^1^ for their interest in our case series, “Pneumocystis jirovecii Pneumonia in Patients Treated for Solid Organ Malignancy.”^2^
We agree that the increasing use of dose-dense chemotherapy regimens makes this clinical situation an important issue. We also agree with the recommendations outlined in their letter—namely that further study of the true incidence of Pneumocystis jirovecii pneumonia in this population is warranted and that raising clinician awareness of the heightened risk of Pneumocystis jirovecii pneumonia can help with early recognition and management.
On behalf of all the authors, please accept our appreciation for the letter.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Khan S, Ahmad B. Comment on “Pneumocystis jirovecii pneumonia in patients treated for solid organ malignancy.” Ochsner J. 2024;24(3). doi: 10.31486/toj.24.0088 · doi ↗
- 2Jackson I, Isern R, Jesina S, Velagapudi M, Pruett W. Pneumocystis jirovecii pneumonia in patients treated for solid organ malignancy. Ochsner J. 2024;24(3). doi: 10.31486/toj.24.0024 · doi ↗